Saturable tissue binding and imirestat pharmacokinetics in rats

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Biochemistry
• Toxicology

Background:

• Aldose reductase inhibitors (ARIs) are investigated for therapeutic potential.
• The pharmacokinetics of imirestat, an ARI, may be influenced by tissue binding.
• Understanding imirestat's disposition is crucial for its clinical application.

Purpose of the Study:

• To investigate if imirestat's pharmacokinetics are affected by saturable tissue binding.
• To characterize the dose-dependent behavior of imirestat in rats.
• To assess the impact of co-administered ARIs on imirestat's disposition.

Main Methods:

• Dose-dependency study in Sprague-Dawley rats using radiolabeled imirestat (2 or 8 mg/kg IV).
• Competition study involving co-administration of imirestat with other ARIs (statil or AL3152).
• Tissue-to-plasma concentration ratio determination in multiple tissues at various time points.

Main Results:

• Steady-state volume of distribution for imirestat was significantly higher at 8 mg/kg compared to 2 mg/kg.
• Co-administration of AL3152 and statil significantly reduced imirestat's steady-state volume of distribution by 63% and 39%, respectively.
• Imirestat tissue/plasma concentration ratios in adrenal glands were markedly reduced by co-administered ARIs.

Conclusions:

• Imirestat exhibits dose-dependent pharmacokinetics in rats, suggesting saturable tissue binding.
• Co-administration with other aldose reductase inhibitors alters imirestat's distribution, confirming competitive binding.
• These findings highlight the importance of considering drug interactions and tissue binding in imirestat's pharmacokinetic profile.